Titlebook: Hughes Syndrome; Antiphospholipid Syn M. A. Khamashta (Deputy Head) Textbook 20001st edition Springer-Verlag London 2000 Antiphospholipid S

閘門

書目名稱Hughes Syndrome影響因子(影響力)




書目名稱Hughes Syndrome影響因子(影響力)學科排名




書目名稱Hughes Syndrome網(wǎng)絡公開度




書目名稱Hughes Syndrome網(wǎng)絡公開度學科排名




書目名稱Hughes Syndrome被引頻次




書目名稱Hughes Syndrome被引頻次學科排名




書目名稱Hughes Syndrome年度引用




書目名稱Hughes Syndrome年度引用學科排名




書目名稱Hughes Syndrome讀者反饋




書目名稱Hughes Syndrome讀者反饋學科排名

投射

M. A. Khamashta (Deputy Head)Eponymous volume - edited by the investigator who defined this syndrome.Contains many color illustrations.Comprehensive coverage by leading authorities

枕墊

http://image.papertrans.cn/h/image/428900.jpg

thalamus

Hemocytopenias in Antiphospholipid SyndromeThrombocytopenia is included among the features of the human antiphospholipid syndrome (APS) [1] and is present in some animal models [2]. Hemolytic anemia can also be found in APS although less frequently than thrombocytopenia [1].

共和國

Cardiac Manifestations in the Antiphospholipid SyndromeA variety of cardiac manifestations have been found in association with antiphospholipid antibodies (aPL), both in patients with systemic lupus erythematosus (SLE) and with the “primary” antiphospholipid syndrome (APS). They mainly include valvular and coronary artery diseases as well as intracardiac thrombus and cardiomyopathy.

他姓手中拿著

muscle-fibers

The Ear and Antiphospholipid SyndromeEvidence now exists that inner-ear pathology is frequently associated with immune dysfunction, including the presence of anti-cardiolipin antibodies (aCL) in the sera of such patients.

狂怒

物質

Antiphospholipid Syndrome: General Featuresristic clinical features of this syndrome although the spectrum of associated symptoms and signs has broadened considerably over the last 15 years. The aim of this chapter is to give a clinical overview and preliminary classification criteria for the APS by way of introduction to the more detailed chapters that follow.

上漲

Kidney Disease in Antiphospholipid Syndromespholipid antibodies (aPL) have received scarce attention. This can be explained because APS was first described in patients with systemic lupus erythematosus (SLE) and such research studies were focussed on the immune-complex-mediated glomerulonephritis rather than renal vascular lesions that could be secondary.